US Patent

US6911461 — 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses

Method of Use · Assigned to UCB SA · Expires 2026-02-21 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects 2-oxo-1-pyrrolidine derivatives and their use as pharmaceuticals, particularly for treating neurological disorders such as epilepsy.

USPTO Abstract

The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

Drugs covered by this patent

Briviact (BRIVARACETAM) · UCB

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2295`	—	Briviact
`U-1815`	—	Briviact
`U-2295`	—	Briviact
`U-2295`	—	Briviact
`U-2295`	—	Briviact
`U-2295`	—	Briviact
`U-2295`	—	Briviact

Patent Metadata

Patent number: US6911461
Jurisdiction: US
Classification: Method of Use
Expires: 2026-02-21
Drug substance claim: Yes
Drug product claim: Yes
Assignee: UCB SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.